Piramal Pharma Limited Announces Results for Q2 and H1 FY27

Piramal Pharma reported Q2FY27 revenue of ₹2,617 crore, up 28% year over year, and EBITDA of ₹385 crore, up 72%, with EBITDA margin expanding to 14.7% from 11.0%. H1FY27 revenue rose 23% to ₹4,887 crore, while EBITDA increased 72% to ₹669 crore; consolidated PAT was ₹5 crore in Q2 versus a ₹99 crore loss a year earlier, but H1 PAT remained a loss of ₹64 crore. The company raised its FY27 revenue-growth outlook to 19%–20% and expects meaningfully higher profitability.

Analysis

The operating leverage is real but not yet equivalent to durable earnings power: EBITDA is improving much faster than sales, while depreciation and interest still absorb much of it, leaving consolidated PAT close to break-even. The key underwriting question is whether CDMO order inflows convert into sustained, higher-margin utilization—not simply a strong quarter or favorable mix. The net-debt increase alongside rising fixed assets, construction in progress and working capital raises the bar for cash conversion; capacity additions that arrive ahead of demand could dilute returns and keep leverage elevated.

Near term, the Oct. 28 call is the catalyst: seek detail on CDMO backlog conversion, segment margins, capex commitments, utilization and operating cash flow. Over 1–3 months, evidence of repeatable margin gains and cash generation would support the upgraded outlook; weak conversion or an H2 slowdown would challenge it. Over 6–18 months, the upside depends on new capacity earning returns above its depreciation and financing burden. Piramal Pharma’s growth is positive for its own competitive position in outsourced development/manufacturing, but no specific competitor displacement is established here. The disclosed AbbVie-linked associate is not enough to infer material earnings exposure for AbbVie; contribution data would be needed. Contrarian angle: the market may reward EBITDA growth while underweighting balance-sheet intensity and the gap between EBITDA and attributable net profit.

Key Decisions for Investors

• Do not chase the initial earnings reaction. Treat Piramal Pharma as a conditional long, with entry after the conference call only if management substantiates order-to-revenue conversion, utilization gains and cash generation; no valuation or price data here supports a target.
• For the next 1–3 months, monitor segment-level margins, operating cash flow versus EBITDA, net debt and capex. A margin guide that is not backed by cash conversion, or further debt growth without clear utilization benefits, would weaken the thesis.
• Use failure to sustain margin improvement or a cut to the upgraded full-year outlook as thesis-falsification signals; also reassess if the call indicates delayed customer programs or capacity coming onstream ahead of demand.
• No direct ABBV position follows from this release: the AbbVie relationship is through an associate/JV, and the article provides no contribution or materiality figures. Verify those disclosures before treating Piramal performance as an AbbVie catalyst.